Limited-Edition Release Continues Distillery’s Celebration of the Art of Blending Through Whiskey, Visual Art and Community

BRECKENRIDGE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) — Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and part of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is turning whiskey into a canvas with the sixth edition of its acclaimed Collectors Art Series. This year’s limited-edition release pairs Breckenridge’s award-winning whiskey-making with the bold, colorful vision of Colorado muralist, professional snowboarder and creative Pat Milbery, whose original label design celebrates the mountain spirit, community and craftsmanship that define Breckenridge.

For this year’s collaboration, the creative partnership comes to life with a new mural by Milbery at Tony P’s Bar & Pizzeria, located at 3000 Zuni St, Denver, CO 80211. The mural brings his signature style and the spirit of the Collectors Art Series into the local community, further reflecting the Distillery’s commitment to supporting artists and creative spaces. Each collaboration transforms a limited-edition whiskey release into a collectible work of art while supporting the creative community through charitable giving.

For Milbery, the collaboration is deeply personal. After moving to Breckenridge to pursue professional snowboarding, the mountain town became the backdrop for many of life’s defining moments, from launching his snowboarding career to discovering his artistic voice. Today, his signature murals can be found across four continents, where bold geometric forms, vibrant color palettes and nature-inspired imagery encourage connection, optimism and open-hearted living.

Inspired by the landscapes, friendships and unforgettable moments that shaped his journey, Milbery’s artwork captures the joyful spirit of Breckenridge through colorful mountain vistas, evergreen forests, radiant sunsets and symbolic elements that honor both community and loved ones who continue to inspire his work. The design also reflects the craft behind whiskey, drawing a parallel between the thoughtful blending of barrels, flavors and character that goes into each expression and Milbery’s own process of bringing together color, movement, memories and emotion to create a singular work of art.

“Everything about Breckenridge inspired the artwork. The friendships. The sunsets. The powder days. The evergreen forests. The crisp mountain mornings. The incredible community,” said Milbery. “The artwork also honors important people in my life, including loved ones who are no longer physically with us but continue to inspire me every day. I wanted the design to represent joyful energy, gratitude, community and the colorful journey that Breckenridge has been in my life.”

Milbery’s artwork will appear on the Breckenridge Barbados Cask Finish Whiskey, bottled at 90 proof and 45% ABV. The limited-edition expression showcases Breckenridge Distillery’s dedication to the art and craft of whiskey, bringing together carefully selected whiskey and the influence of Barbados cask finishing to create a distinctive expression. Just as Milbery thoughtfully layers color, texture and movement to create his artwork, Breckenridge’s whiskey-making process brings together distinct elements, from spirit and barrel to time and finishing, to create a finished whiskey with its own character and story.

Since its inception, the Collectors Art Series has become one of Breckenridge Distillery’s signature annual releases, highlighting acclaimed artists while reinforcing the Distillery’s longstanding support of the arts. Previous collaborators include Miles Toland, Abby Wren and Alexandrea Pangburn, each bringing a unique perspective to the series while helping raise funds for organizations that champion artists and creative spaces.

Breckenridge Collectors Art Series releases have earned numerous accolades, including 2023 Best Blended LTD Release and 2020 Icons of Whisky’s Campaign Innovator of the Year at the World Whiskies Awards, along with Gold and Double Gold medals at the San Francisco World Spirits Competition.

Breckenridge Collectors Art Series 6 will be available beginning September 15, 2026, exclusively at Breckenridge Distillery and the Main Street Tasting Room in Breckenridge, Colorado, for $125.

For more information about Breckenridge Distillery, visit breckenridgedistillery.com. Follow Breckenridge on Instagram @breckdistillery and become a fan at facebook.com/BreckDistillery. Age 21+. Always enjoy responsibly.

To learn more about Pat Milbery and view his work, visit Heart Space Studios at heartspacestudios.art, patmilbery.com and Sognar Creative Division at sognarcreativedivision.com, and follow @patmilbery on Instagram.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

About Breckenridge Distillery

Founded in Colorado in 2008, Breckenridge Distillery is the “World’s Highest Distillery,” and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey.

One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended winner at the World Whiskies Awards by Whisky Magazine and a 4x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World’s Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World’s Best Blended Whiskey and Breckenridge Gin, named World’s Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 6 Double Golds at the San Francisco World Spirits Competition.

The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named as one of the country’s Top Visitor Attractions by Whisky Magazine, guests can dine at their award-winning restaurant, enjoy show-stopping cocktails, learn about their highly awarded spirits with an in-depth tasting, and get an inside look at their active production facility. New to the distillery, guests have the opportunity to blend their own whiskey as they learn the inner workings of whiskey production.

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life.

To learn more about Breckenridge Distillery, visit www.breckenridgedistillery.com. Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at facebook.com/BreckDistillery. 

For more information about Tilray Brands, visit www.tilray.com and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact

Media: news@tilray.com
Investors: investors@tilray.com
Breckenridge Distillery: jessie.unruh@breckenridgedistillery.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/c5107390-6a4e-49c9-a6a6-5f845427c134

https://www.globenewswire.com/NewsRoom/AttachmentNg/209f298a-228f-4040-bd31-cf0762d63ba8

Agreement geared towards potential orders of up to 1 tonne of titanium powder per month

MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, today announces its first contract toward a new titanium powder supply agreement with a U.S.-based materials distributor (the “Client”). The powder for this order has been produced by PyroGenesis’ NexGen™ plasma atomization process and is to be shipped this week. The Client’s identity and contract details will remain confidential for competitive reasons.

As disclosed in the Outlook section of the Company’s Q2 2026 earnings release, dated August 6, 2026, the Company has been in discussion with several companies regarding titanium powder orders, including a US-based materials distributor for a monthly supply agreement of up to 500 kg. Today’s contract represents the first commercial order arising from those discussions. The Client has since indicated that its potential monthly requirements could reach 1,000 kg (1 tonne); however, no commitment for recurring orders at that volume has been made.

The order is for Ti64 “fine” cut powder, with a particle size range of 20-80µm (microns). This powder is typically used in laser powder bed fusion (LPBF), an additive manufacturing technology widely used to produce complex, high-density components for aerospace, healthcare, and automotive industries. The Client supplies U.S. customers in the aerospace, defense, energy, and broader advanced manufacturing sectors.

“The contract announced today directly supports the strategic goals outlined in our April 29, 2026, press release: positioning the Additive Manufacturing Division for its next level of growth, with operations anticipated to be several times larger than those currently in place,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “This relationship with a well-connected materials distributor serving both the aerospace and defense sectors will help us expand our customer base in these two key industries that we have identified as central to achieving those strategic goals.”

PyroGenesis’ Technology Development for Additive Manufacturing

PyroGenesis is the inventor of the plasma atomization process and in fact coined the term “plasma atomization” in its original patent. Plasma atomization is often considered the gold standard process for the production of metal powder for additive manufacturing, also referred to as metal 3D printing.

After years of R&D, PyroGenesis redesigned its plasma atomization technology and launched NexGen™ to re-enter the powder production market by targeting higher quality and yields, at lower operating costs. The Company has since taken a deliberate approach to commercialization, progressing from gram-scale customer samples to 100-kg orders, and its first tonne-scale order in May 2023.

PyroGenesis produces titanium powders in particle size distribution ranges across three “cuts”:

  • Fine Cut, in particle sizes between 15–63 µm for use in laser powder bed fusion (LPBF).
  • Coarse Cut, in particle sizes between 45–106 µm for use in electron beam melting (EBM) and 45–150 µm in directed energy deposition (DED).
  • Off-Cuts, in particle sizes not currently used by the existing range of commercial printers, but which offers a high-quality feedstock for use in the production of high-quality metal alloys.

PyroGenesis’ titanium metal powder as produced by its NexGen™ plasma atomization system.

Image: PyroGenesis’ titanium metal powder as produced by its NexGen™ plasma atomization system.

INDUSTRY AND MARKET CONTEXT

  • The global 3D printing market specific to titanium powder is expected to increase from $214 million in 2023 to $1.4 billion by 2032.1
  • Titanium is classified as a critical mineral by both Canada2 and the U.S.3
  • Titanium is used by multiple industries, including space, aerospace, defense, consumer electronics, medical, hydrogen, and electric vehicles, due to its high strength-to-weight ratio and corrosion resistance.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

_____________________
1
https://3dprint.com/313549/titanium-3d-printing-powders-to-reach-1-4b-by-2032/

2 https://www.canada.ca/en/campaign/critical-minerals-in-canada/critical-minerals-an-opportunity-for-canada.html

3 https://public-inspection.federalregister.gov/2025-16311.pdf

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b8b5bea-6909-44b7-ac08-2664cd5c55ab

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) announces that it has received an unsolicited offer from an arm’s length third party for a proposed transaction for the sale of substantially all of the assets of CLC. The proposed transaction involves a different potential buyer and is not related to the proposed transaction announced by CLC on August 21, 2026. CLC has entered into a non-binding letter of intent in respect of the second offer.

The Special Committee of the Board of Directors (the “Special Committee“) formed in August 2026 will review the merits of the proposed transaction. The Special Committee is also continuing to review the merits of the original transaction proposal announced on August 21, 2026.   The Board of Directors of CLC has not approved the entering into of any definitive agreement for either transaction at this time. See “Special Committee” below.

Original Transaction

On August 21, 2026, CLC announced in a press release (the “August 21 Press Release“) that it had entered into a non-binding letter of intent (the “Initial LOI“) with a private Alberta corporation (the “Original Purchaser“), to engage in due diligence and negotiations regarding the terms of a proposed transaction (the “Original Transaction“) whereby the Original Purchaser would acquire all of the issued and outstanding common shares (the “Shares“) of the Company. The final structure of the Proposed Transaction has not been determined and, if the parties agree to proceed, will be set out in a definitive agreement between CLC and the Original Purchaser.

The Initial LOI contemplates an aggregate transaction value of $15,000,000 for 100% of the equity of the Company on a fully-diluted, cash-free, debt-free basis. The Initial LOI is non-binding and there can be no assurance that a definitive agreement for the Original Transaction will be entered into or that the Original Transaction contemplated by the Initial LOI, or any other transaction, will be completed.

Alternative Transaction

Subsequent to the execution of the Initial LOI and the issuance of the August 21 Press Release, the Company received an unsolicited offer from Medical Saints Ltd. an arm’s length third party (the “Alternative Purchaser“) for the sale of substantially all of the assets of CLC (the “Alternative Transaction“). In connection with the fiduciary obligations of the Board and the Special Committee, and as permitted by the exclusivity provisions of the Initial LOI, the Company entered into a non-binding letter of intent with the Alternative Purchaser effective September 11, 2026 for an Alternative Transaction (the “Second LOI”). No definitive agreement has been entered into in respect of the Original Transaction or the Alternative Transaction. “We are extremely pleased to move forward with the acquisition of the Christina Lake Cannabis assets. The scale of the cultivation platform is significant, but what makes this transaction particularly strategic for Medical Saints is the extraction infrastructure, processing capabilities, and expertise that Christina Lake has built. These assets complement our existing operations and materially expand what we can produce, process, and bring to market. Lucas Leone – Chief Executive Officer, Medical Saints Ltd.”

Unlike the Original Transaction, which contemplates an acquisition of the Shares, the Alternative Transaction contemplates the acquisition by the Alternative Purchaser of all of the assets of the Company (other than cash, cash equivalents, tax receivables and certain other assets to be agreed as excluded), free and clear of any encumbrances. The assets to be acquired would include all owned land and buildings and assigned commercial leases used in the business, all machinery, office equipment, computers, furniture and inventory, and all customer lists, proprietary data, historical records, trademarks, patents, copyrights and software.

The Second LOI provides for an aggregate purchase price of $18,000,000, on a cash-free, debt-free basis, payable in cash at closing and inclusive of a $2,000,000 advance payment on the purchase price (the “Advance”). The Advance would be delivered to the Company’s counsel, for the benefit of the Company, concurrently with the execution of a definitive agreement and would be credited against the purchase price at closing. In certain circumstances in which the transaction does not close as a result of the Alternative Purchaser’s failure to fund or a material breach by the Alternative Purchaser, the Advance would be retained by the Company as liquidated damages; in other circumstances, including a failure to close not caused by the Alternative Purchaser or a breach by the Company, the Advance would be repaid to the Alternative Purchaser.

Under the Second LOI, the parties would negotiate and enter into a definitive agreement for the Alternative Transaction within 40 days of executing the Second LOI, and would use reasonable commercial efforts to work towards a closing following the satisfaction or waiver of the applicable closing conditions. The Second LOI provides for an exclusivity period of 40 days, which is expressly subject at all times to the fiduciary duties of the Board, including its ability to consider, negotiate or respond to unsolicited bona fide proposals, and which is expressly subordinate to the Company’s existing contractual obligations to third parties, including its obligations under the Initial LOI.

Completion of the Alternative Transaction would be subject to a number of conditions, including the release and discharge of any encumbrances, negotiation and execution of a mutually agreed definitive agreement, receipt of all required regulatory, stock exchange, corporate and shareholder approvals, confirmation that no material adverse change has occurred, and the entering into of mutually agreed employment, consulting and/or transition services arrangements. The Alternative Purchaser is expected to offer employment to all of the Company’s employees engaged in the business on substantially comparable terms, with any related severance, termination or similar liabilities to be for the account of the Alternative Purchaser.

Term

The Second LOI will terminate in the following circumstances: (a) by written agreement of the parties; (b) upon the execution of a definitive agreement between CLC and the Alternative Purchaser; or (c) at the end of the exclusivity period (or any extension thereof).

Special Committee

A Special Committee of the Board (the “Special Committee“) was formed in August 2026 as described in the August 21 Press Release. The Special Committee’s role is to consider, evaluate and, if applicable, negotiate the strategic alternatives available to the Company, including the Original Transaction and the Alternative Transaction, and to make recommendations to the Board in connection therewith, including prior to the execution of any definitive agreement or the submission of any such transaction to the shareholders of the Company for a vote.   The Board of Directors of CLC has not approved the entering into of any definitive agreement for either transaction at this time.

Second LOI Non-Binding

The Second LOI is non-binding and does not create any binding legal rights or obligations, other than certain customary provisions – namely those relating to Legal Effect, Exclusivity, Termination, Confidentiality, Public Disclosure and General Provisions – which are binding upon execution. The Second LOI is governed by the laws of the Province of Ontario. As negotiations are ongoing, the Company can provide no assurance that it will agree on the final terms of, or execute, a definitive agreement with the Alternative Purchaser, or that the Alternative Transaction will be completed. Any such transaction would be subject to, among other conditions, the negotiation and execution of a definitive agreement and the receipt of all required shareholder, regulatory, stock exchange and other approvals.

If a definitive agreement with the Alternative Purchaser is executed, the Company expects that it will be required to hold a special meeting (the “Special Meeting“) of the Company’s shareholders to approve the Alternative Transaction. The Alternative Transaction is subject to receipt of the foregoing approvals and other customary closing conditions. Terms and conditions of the Alternative Transaction are expected to be disclosed in greater detail in a management information circular for the Special Meeting (the “Circular“). Following execution of the definitive Agreement, a Circular will be mailed to the Company’s shareholders. There are no finder’s fees payable by the Company in connection with the Alternative Transaction.

In the event that the Company executes a definitive agreement with either the Original Purchaser or the Alternative Purchaser, copies of such definitive agreement and the information circular for the special meeting of the Company’s shareholders to approve such transaction will be filed with Canadian securities regulators. Documents filed by the Company with Canadian securities regulators are available on the SEDAR+ profile of the Company at www.sedarplus.ca. Shareholders are urged to read any relevant materials when they become available. However, Shareholders do not need to take any action with respect to the Original Transaction or the Alternative Transaction at this time.

Counsel

Prelia Canada LLP is acting as the Company’s legal advisor.

About Christina Lake Cannabis Corp.

Christina Lake Cannabis is a licensed producer of cannabis under the Cannabis Act with a standard cultivation license and corresponding processing amendment from Health Canada as well as a research and development license. Christina Lake Cannabis’ facilities consist of a 32-acre property, which includes over 950,000 square feet of outdoor grow space, offices, propagation and drying rooms, research facilities, and a facility dedicated to processing and extraction, and a 342-acre property which includes approximately 100 acres of licensed outdoor grow space, greenhouses, and a dry room. CLC focuses its production on creating high-quality outdoor flower, extracts and distillate for its B2B client base.

On behalf of Christina Lake Cannabis:

“Jay McMillan”
Jay McMillan, Chairman

For more information about CLC, please visit: www.christinalakecannabis.com

Investor Relations and Media Inquiries
investors@clcannabis.com
1.888.410.0304

About Medical Saints Ltd:
Medical Saints Ltd. is one of Canada’s largest privately held federally licensed cannabis producers, operating a vertically integrated platform across cultivation, processing, manufacturing, product development and commercialization.

Medical Saints currently produces 100 tonnes (100,000 kilograms) of cannabis annually in Canada.

For more information, visit www.medicalsaints.com.

Media & Investor Contact:
Lucas Leone
Chief Executive Officer
Medical Saints Ltd.
Email: info@medicalsaints.com

THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

All statements, other than statements of historical fact, contained in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of certain securities laws and are based on expectations and projections as of the date of this press release. Forward-looking information and forward-looking statements may relate to the Company, the Original Purchaser, the Alternative Purchaser, and to anticipated events or results, notably the negotiation and potential completion of the Original Transaction and/or the Alternative Transaction on terms substantially similar to those currently contemplated.

Statements regarding future results, performance, achievements, prospects, or opportunities of the Company, the Original Purchaser, the Alternative Purchaser, or similar statements concerning anticipated future events, results, circumstances, performance or expectations, notably the execution of a definitive agreement and the completion of a transaction with the Original Purchaser or the Alternative Purchaser, are also forward-looking statements. Forward-looking statements contained in this press release include, without limitation, those related to: (i) the Board’s review and evaluation of the Second LOI; (ii) the relative benefits to the Company and its shareholders of the Original Transaction and the Alternative Transaction; (iii) the ability of the Company and either the Original Purchaser or the Alternative Purchaser to negotiate and execute a definitive agreement; (iv) the Company’s receipt of all necessary approvals (including shareholder approval, any required court approval, regulatory and stock exchange approvals, and any approvals required in connection with the transfer or reissuance of the Company’s licences); and (v) the final terms of any definitive agreement.

Forward-looking statements are based on expectations, estimates, and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, the Original Purchaser or the Alternative Purchaser as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that the Company, the Special Committee, and the Board will be able to negotiate or approve a definitive Agreement on terms acceptable to each of them and to either the Original Purchaser or the Alternative Purchaser, as applicable. Future events could differ materially from what is currently anticipated by the Company, the Original Purchaser or the Alternative Purchaser.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions, and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Company’s other filings with the securities regulators of Canada including, but not limited to, the cautionary statements made in the relevant portion of the Company’s Management Discussion & Analysis prepared as of June 29, 2026, for the financial year ended February 28, 2026. The foregoing list of factors that may affect future results is not exhaustive and new, unforeseeable risks may arise from time to time. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the launch of VitalHub AI Scribe, an ambient clinical intelligence (“ACI”) solution that captures conversations, identifies clinically relevant information, and automatically generates documentation, including case notes, transcriptions, client summaries, and patient summaries. By transforming conversations into structured documentation, AI Scribe helps health and human services professionals spend more time with patients and clients and less time completing paperwork. AI Scribe is going to be offered in VitalHub’s CaseWORKS and TREAT solutions.

Designed to scale across the VitalHub portfolio, AI Scribe brings practical AI capabilities directly into existing solutions. As a natively embedded module, the solution integrates seamlessly into the workflows organizations already rely on, enabling adoption without additional systems, interfaces, or disruption to daily operations.

AI Scribe is part of VitalHub’s growing investment in AI-powered capabilities. As both a developer and acquirer of best-of-breed software solutions, VitalHub is uniquely positioned to embed AI solutions across a broad range of workflows, delivering scalable technologies that help customers meet evolving demands while remaining focused on the people they serve.

Canadian Mental Health Association Waterloo Wellington (“CMHA WW”) became the first organization to deploy VitalHub AI Scribe through the CaseWORKS case management solution. Beginning with its intake teams, CMHA WW will benefit from AI-assisted documentation to improve efficiency, staff productivity, and client service delivery.

CaseWORKS and TREAT collectively support an initial serviceable market of approximately 22,000 practitioners. This expansion demonstrates the portability of VitalHub’s AI capabilities across its product portfolio and provides a repeatable model for delivering new functionality through the software environments customers and practitioners already use.

“AI Scribe reflects VitalHub’s approach to delivering practical AI that addresses real-world challenges for our customers,” said Dan Matlow, CEO of VitalHub. “We see significant opportunities to extend this capability across our portfolio and are pleased to begin with CMHA WW.”

“Our staff are passionate about supporting the individuals that we serve, and are often burdened by documentation requirements that continue to grow,” said Helen Fishburn, CEO of CMHA WW. “We sought a solution that could help reduce time spent on administrative tasks without disrupting how our staff work. The AI Scribe module is helping to streamline documentation, and giving our team members more time to focus on what matters most, supporting our clients and community.”

About VitalHub

VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub’s comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,300 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 700 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit www.vitalhub.com and LinkedIn.

About Canadian Mental Health Association Waterloo Wellington

The Canadian Mental Health Association Waterloo Wellington is a non-profit organization that provides a full care system for those with addictions, mental health or developmental needs. We serve everyone from children to adults to seniors, all under one roof. Our programs help individuals and families to lead lives filled with meaning and promise. We have 450 staff at offices in Cambridge, Waterloo, Kitchener, Guelph, Fergus, and Mount Forest. We also provide visiting/satellite services in Arthur, Shelburne, Erin, and Palmerston. For more information, please visit www.cmhaww.ca.

Contact Information

Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
christian.sgro@vitalhub.com

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@vitalhub.com

Cautionary Statement

Certain statements contained in this news release may constitute “forward-looking information” or “financial outlook” within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Independent evaluation finds the regulated supply chain functioning positively and gaining preference with consumers

Company remains a committed community partner; sees opportunities for stronger consumer protections to create a model framework reflective of Dutch leadership and innovation

GRONINGEN, Netherlands, Sept. 15, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today welcomed the publication of the first-year findings from the Netherlands’ regulated cannabis program, and reaffirmed its long-term commitment to the program and to the Dutch communities in which it operates. Village Farms Netherlands participates in the program as one of ten producers licensed by the Dutch government to cultivate and distribute cannabis to participating coffeeshops.

The evaluation, conducted by the Trimbos Institute, RAND Europe and Breuer & Intraval on behalf of the Dutch government, assessed the first year of the program’s operational phase across the ten participating municipalities. It reported that stakeholders across the supply chain, including coffeeshops, growers, municipalities and regulators, described their early experiences as positive, and that product range widened, with consumers rating price-value more positively than before the experiment began. It recorded no clear difference in public health, livability or safety compared to non-participating municipalities.

Michael DeGiglio, President and Chief Executive Officer of Village Farms, commented, “What the Dutch government set out to do was a historic undertaking for regulated cannabis in Europe and it deserves considerable praise. Replacing a tolerated supply chain with a regulated one is not an easy task, but these first-year findings are an encouraging sign of early success. We’re invested here as long-term community partners, and our team remains committed to collaborating with local stakeholders to build a successful program that protects consumers and creates economic benefits for its local communities.”

Orville Bovenschen, President of Global Operations for Village Farms, oversees operations for the Company’s two Dutch facilities.

Bovenschen commented, “What we bring to the Netherlands goes well beyond cannabis. We draw on decades of experience in controlled environment agriculture and regulated markets, with expertise in process innovation and product quality, compliance and responsible operations. We’ve applied those lessons while working closely with our local municipalities to meet the requirements of this new regulated market, and we’ll continue sharing our experience and insight with Dutch policymakers and regulators to build a model framework reflective of Dutch leadership and innovation.”

Bovenschen added, “We’re encouraged by these positive initial results, and we believe now is an appropriate time for the government to begin talking about ways to create stronger protections for consumers and longer-term certainty for the program. We are supportive of revisions to packaging and labeling requirements to avoid consumer preferences shifting to high potency products, and also see benefits to further expansion of the program to combat the illicit market. Getting these conversations started will give growers, coffeeshops, and municipalities the confidence to plan and invest for a much larger, successful regulated market.”

About Village Farms International

Village Farms is a global leader in cannabis, plant-based consumer packaged goods, and sustainable innovation. With a legacy built on decades of Controlled Environment Agriculture expertise and Dutch farming practices, today the Company is one of the world’s largest and most profitable cannabis operators with an asset portfolio that spans over 7 million square feet of advanced greenhouse and indoor cultivation assets.

In Canada, Village Farms operates the world’s largest EU-GMP certified cannabis facility at its production campus in Delta, British Columbia, and exports products to international medical markets. The Company is also a market share leader in dried flower formats and produces and distributes some of the country’s highest quality and best-selling strains, including its flagship Pure Sunfarms Pink Kush, one of the most widely consumed strains on the planet. Village Farms’ Canadian brand portfolio includes Pure Sunfarms, Fraser Valley Weed Co., Soar, Super Toast, Pure Laine, Tam Tams and Promenade.

In the Netherlands, the Company is one of only ten licensed operators in the country’s regulated cannabis program, and in the United States its CBDistillery brand is one of the country’s premier cannabinoid wellness platforms, and it also holds equity interests in cannabis businesses in Australia and Germany. Beyond cannabis, the Company holds an equity interest in Verdexa Holdings, a private venture pursuing strategic acquisitions to build a premier branded food platform, and its Clean Energy division transforms landfill gas into renewable natural gas and receives royalties on all revenues generated.

Contacts

Sam Gibbons, SVP, Corporate Affairs Email: sgibbons@villagefarms.com

Danielle Allore, Senior Manager, Communications Email: dallore@villagefarms.com

MISSISSAUGA, Ontario, Sept. 15, 2026 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (“Next Hydrogen” or the “Company”) is pleased to announce that it has secured a non-repayable contribution agreement with the Government of Canada through Natural Resources Canada’s Energy Innovation Program (NRCan) for funding of up to $2 million for additional research to develop scalable fabrication processes for commercial electrolyzer modules.

This funding will support R&D activities focused on improving the efficiency, performance and cost of Next Hydrogen’s commercial electrolyzer modules. As an initial project milestone, the Company is targeting cell performance of 1.8 V/cell at 1.0 A/cm² by Q1 2027, consistent with the U.S. Department of Energy (DOE) 2026 technical target for alkaline water electrolysis. The project’s ultimate performance target is 1.7 V/cell at 1.2 A/cm², targeted for achievement by September 2028.

The technologies developed through this project are expected to enhance the competitiveness of Next Hydrogen’s commercial products by lowering energy consumption and reducing the cost of green hydrogen production. As electricity accounts for 60–70% of hydrogen production operating costs, these efficiency gains are expected to reduce electricity consumption of its electrolyzer modules per kilogram of hydrogen produced by approximately 8% as well as reducing the cost of fabricating its electrolyzers.

We anticipate achieving the initial 1.8 V/cell at 1.0 A/cm² performance milestone by Q1 2027, with the project continuing toward the ultimate target of 1.7 V/cell at 1.2 A/cm² by September 2028.

“We are grateful for NRCan’s support of this important initiative,” said Jocelyne Moyer, President and CEO of Next Hydrogen. “This investment will help advance our electrolyzer technology to have performance levels aligned with the U.S. DOE/H2NEW long-term vision for alkaline water electrolysis while supporting lower hydrogen production costs for our customers. We expect the innovations developed through this project to be incorporated into our commercial electrolyzer platform in early 2027, further enhancing its efficiency and competitiveness. By improving project economics and making clean hydrogen more affordable, this initiative can help accelerate market adoption while reinforcing Canada’s leadership in hydrogen innovation and the transition to a low-carbon economy.”

“Building Canada’s energy future depends on building and scaling the technologies that will power our economy for decades to come. Investments in Canadian innovators like Next Hydrogen are strengthening our energy security, supporting growth and turning Canadian expertise into real-world solutions. By supporting innovation today, we are building the stronger, more competitive energy sector Canada needs for generations to come.” said the Honourable Tim Hodgson, Minister of Energy and Natural Resources.

About Next Hydrogen

Founded in 2007, Next Hydrogen is a designer and manufacturer of electrolyzers that use water and electricity to generate clean hydrogen for use as a clean energy source. Next Hydrogen’s unique cell design architecture supported by over 40 patents enables superior dynamic response to efficiently convert intermittent renewable electricity into green hydrogen on a commercial infrastructure scale.

Contact Information

Jocelyne Moyer, President and CEO
Email: jmoyer@nexthydrogen.com
Phone: 416-317-0566

www.nexthydrogen.com

Cautionary Statements

This news release contains “forward-looking information” and “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the risks associated with the hydrogen industry in general; delays or changes in plans with respect to infrastructure development or capital expenditures; cell efficiency targets; expected order sizes for the product line; customer relationships and customer terms for testing of products at a customer site; the ability of the Corporation to optimize energy efficiencies; the Corporation’s available resources to grow its sales backlog; uncertainty with respect to the timing of any contemplated transactions or partnerships, or whether such contemplated transactions or partnerships will be completed at all; whether the uncertainty of estimates and projections relating to costs and expenses; failure to obtain necessary regulatory approvals; health, safety and environmental risks; uncertainties resulting from potential delays or changes in plans with respect to infrastructure developments or capital expenditures; currency exchange rate fluctuations; as well as general economic conditions, stock market volatility and the ability to access sufficient capital. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, there will be no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Strategic Highlights: 

  1. Palomino Laboratories, Inc. Co-founder Steven P. DenBaars will present at MicroLED Connect 2026 on Thursday, September 17, 2026, at 11:50 a.m. (Central European Time) at the High Tech Campus in Eindhoven, the Netherlands.
  2. DenBaars’ presentation, “Development of GaN Based MicroLED Devices for Full Color Displays and High-Speed Optical Communication,” will highlight the role of improved microLED device design in enabling higher-speed data transmission and the potential for energy-efficient optical interconnects supporting AI infrastructure and data-center applications.

GOLETA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Palomino Laboratories, Inc. (OTCQB: PALX) (‘Palomino’ or the ‘Company’), an artificial intelligence (AI) interconnect technology company, today announced that Co-founder and Director Steven P. DenBaars will present at MicroLED Connect 2026 on Thursday, September 17, 2026, at 11:50 a.m. CEST at the High Tech Campus in Eindhoven, the Netherlands.

Professor DenBaars’ presentation, “Development of GaN Based MicroLED Devices for Full Color Displays and High Speed Optical Communication,” will highlight advances in gallium nitride (GaN) microLED materials, device efficiency, and integration approaches supporting next-generation display and optical communication applications. The presentation will address how improved microLED device design can support higher-speed data transmission and the potential for energy-efficient optical interconnects for AI infrastructure and data-center environments.

Jeffrey B. Shealy, Co-Founder and CEO, commented: “AI infrastructure is being constrained by power and bandwidth limits in short-reach data movement, and the next wave of optical interconnect innovation will be defined by higher efficiency and higher speed in compact form factors.” Mr. Shealy continued, “Prof. DenBaars’ presentation at MicroLED Connect 2026 highlights advances in GaN-based microLED devices that can help enable faster data transmission and more energy-efficient optical interconnects for AI and data-center environments. As Palomino advances its roadmap, we believe microLED-enabled optical interconnects represent a compelling opportunity to improve performance-per-watt across next-generation AI systems.”

MicroLED Connect 2026 is hosted at the High Tech Campus in Eindhoven, the Netherlands. Additional conference information is available here.

About Palomino Laboratories

Palomino Laboratories is an artificial intelligence (AI) interconnect technology company headquartered in Goleta, California, developing next-generation connectivity solutions for the rapidly evolving AI infrastructure market. The Company’s product focus addresses AI interconnect solutions in the 0-to-50 meters range and includes: (i) silicon chipsets enhancing the speed of copper, (ii) silicon optical integrated circuits (IC’s) optimizing the performance of MicroVCSEL interconnects, and (iii) silicon and gallium nitride IC’s for MicroLED interconnects. Our chipsets enable high-bandwidth, low-latency, and energy-efficient data movement across AI systems. Palomino’s solutions are designed to support the growing performance demands of AI, high-performance computing (HPC), enterprise networking, hyperscale data centers and advanced robotics as increasingly intelligent systems require faster, more efficient, and more reliable data connectivity.

For more information, please visit www.palominolabs.ai.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the factors listed under “Risk Factors” in the Company’s filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For further information
Palomino Laboratories Inc.
Jeffrey B. Shealy, CEO
Email: IR@palominolabs.ai

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Lahontan Gold Corp. (TSXV:LG, OTCQB:LGCXF, FSE:Y2F) (the “Company” or “Lahontan”) is pleased to announce additional results from its 2026 Sonic core drilling program at the Santa Fe Mine Project. The ten drill holes reported below were all located on Santa Fe Mine Heap Leach Pad Two (“HLP Two”) and total 168.9 metres. Nearly every drill interval (0.76m) contains meaningful gold and silver mineralization, not unexpected given that the program is evaluating a historic heap leach pad (please see table and map below).

2026-09-14 at 6.54.17 PM

Notes: Au Eq equals Au (g/t) + ((Ag g/t/60)*0.70). Silver grade for calculating Au Eq is adjusted to consider historic metallurgical recovery as described in the Santa Fe Project Technical Report*. All drill holes are vertical, true thickness of the intercepts are approximately 100% of the drilled interval. Numbers may not total precisely due to rounding.

HLP Two was utilized by Corona Gold to process run-of mine (“ROM” or uncrushed) gold and silver mineralized rock from the Santa Fe open pit during the late 1980’s and early 1990’s. Detailed production records show that 3.76M tonnes of rock grading 0.55 g/t Au, 2.9 g/t Ag (0.58 g/t Au Eq) was loaded on HLP Two and, based on reported recoveries (47% Au, 13% Ag), the expected residual grade would average about 0.29 g/t Au and 2.5 g/t Ag (0.32 g/t Au Eq). Based on these first ten drill holes (out of 26 completed), the weighted average grade of all samples to date is 0.50 g/t Au, 3.3 g/t Ag (0.54 g/t Au Eq). CN Au analyses vary from to 5 to 82% of the coresponing fire assay Au value and average 40%, suggesting that the heap leach pad material may be amenable to reprocessing using conventional CN leaching. Unique to drilling heap leach pads, mine dumps, or tailings, is a lack of systematic geologic or other technical controls to grade distribution, so grade variability is expected.

Kimberly Ann, Founder, Chair, CEO, and President of Lahontan Gold Corp commented: “The results from the Sonic core drilling of HLP Two are very encouraging. The drill holes confirm the presence of significant residual gold and silver mineralization in HLP Two. Additional drill results will be needed before Mineral Resources can be calculated; however, the program is clearly off to an excellent start. There are 86 additional Sonic drill holes spread across the four historic heap leach pads, so expect additional results as assays are provided by the lab.”

Screenshot 2026-09-14 at 6.55.43 PM

Drill hole location, Heap Leach Pad Two, Santa Fe Mine Project, Mineral County, Nevada. Drill holes shown are the SF26-XXXS series of Sonic core drill holes.

QA/QC Protocols

Lahontan conducts an industry standard QA/QC program for its core, Sonic, and RC drilling programs. The QA/QC program consisted of the insertion of coarse blanks and Certified Reference Materials (CRM) into the sample stream at random intervals. The targeted rate of insertion was one QA/QC sample for every 16 to 20 samples. Coarse blanks were inserted at a rate of one coarse blank for every 65 samples or approximately 1.5% of the total samples. CRMs were inserted at a rate of one CRM for every 20 samples or approximately 5% of the total samples.

The standards utilized include three gold CRMs and one blank CRM that were purchased from MEG, LLC of Lamoille, Nevada (formerly Shea Clark Smith Laboratories of Reno, Nevada). Expected gold values are 0.188 g/t, 1.107 g/t, 10.188 g/t, and -0.005 g/t, respectively. CRMs with similar grades are inserted as the initial CRM’s run out. The coarse blank material comprised of commercially available landscape gravel and unaltered Tertiary volcanic rock have an expected gold value of -0.005 g/t.

As part of the RC drilling QA/QC process, duplicate samples were collected of every 20th sample interval at the drill rig to evaluate sampling methodology. Samples were collected from the reject splitter on the drill rig cyclone splitter. Samples were collected at each 95- to 100-foot (28.96 – 30.48m) mark and labeled with a “D” suffix on the sample bag. No duplicates were submitted for Sonic core drill holes.

All drill samples were sent to American Assay Laboratories (AAL) in Sparks, Nevada, USA for analyses. Delivery to the lab was either by a Lahontan Gold employee or by an AAL driver. Analyses for all RC and core samples consisted of Au analysis using 30-gram fire assay with ICP finish, along with a 36-element geochemistry analysis performed on each sample utilizing two acid digestion ICP-AES method. Tellurium or 50-element analyses were performed on select drill holes utilizing ICP-MS method. Cyanide leach analyses, using a tumble time of 2 hours and analyzed with ICP-AES method, were performed on select drill holes for Au and Ag recovery. AAL inserts their own blanks, standards and conducts duplicate analyses to ensure proper sample preparation and equipment calibration. We have all results reported in grams per tonne (g/t).

About Lahontan Gold Corp.

Lahontan Gold Corp. is a Nevada-focused mine development company advancing a portfolio of four gold and silver projects in mining-friendly Nevada’s prolific Walker Lane. The Company’s primary focus is the restart of its flagship, the 28.3 km² Santa Fe Mine project, with a targeted return to production in 2027.

  • Santa Fe Mine historic production: 359,202 ounces of gold and 702,067 ounces of silver, open pit mining with heap-leach processing (1988-1995; Nevada Bureau of Mines).
  • Current Resources: The Santa Fe Mine has a NI 43-101 compliant Indicated Mineral Resource of 1,195,000 oz Au Eq (47,532,000 tonnes grading 0.72 g/t Au and 5.55 g/t Ag, together grading 0.78 g/t Au Eq) and an Inferred Mineral Resource of 1,190,000 oz Au Eq (60,605,000 tonnes grading 0.59 g/t Au and 2.40 g/t Ag, together grading 0.61 g/t Au Eq), all pit constrained (Au Eq is inclusive of recovery, please see Santa Fe Project Technical Report and note below*).
  • Objectives 2026:
    • Complete an updated Preliminary Economic Assessment (“PEA”) for the Santa Fe Mine, including the first analysis of mining and processing sulfide resources,
    • Advancing mine permitting activities with the objective of commencing construction in 2027,
    • Continue drill testing the satellite West Santa Fe project, with a maiden resource estimate targeted by year-end,
    • Conduct exploration drilling at Santa Fe focused on expanding known gold and silver mineralization,
    • Drill test historic heap-leach pads to evaluate residual gold and silver mineralization for potential future reprocessing opportunities.

For more information, please visit our website: www.lahontangoldcorp.com

* Please see the “Updated Mineral Resource Estimate, NI 43-101 Technical Report, Santa Fe Project”, Authors: Michael S. Lindholm, C.P.G., and Thomas Dyer, PE; Effective Date: August 13, 2026, Report Date: Maximum 45 days from August 17, 2026. The Technical Report will be available on the Company’s website and SEDAR+. Mineral resources are reported using a cut-off grade of 0.10 g/t AuEq for oxide and transition resources and 0.30 g/t AuEq for non-oxide resources. AuEq for the purpose of cut-off grade and reporting the Mineral Resources is based on the following assumptions gold price of US$3,250/oz gold, silver price of US$40.00/oz silver, and oxide gold recoveries ranging from 60% to 79%, oxide silver recoveries ranging from 0% to 30%, transitional gold recoveries ranging from 28% to 45%, transitional silver recoveries ranging from 0 to 13%, and non-oxide gold and silver recoveries of 68% except for the York deposit where non-oxide recoveries are estimated to be 0%.

Qualified Person

Brian J. Maher, M.Sc., CPG-12342, is a “Qualified Person” as defined under Canadian National Instrument 43-101, Standards of Disclosure for Mineral Projects, and has reviewed and approved the content of this news release in respect of all technical disclosure other than the Mineral Resource Estimate as noted above.‎ Mr. Maher is Senior Vice President, Mine Development & Exploration for Lahontan Gold and has verified the data disclosed in this news release, including the sampling, ‎‎analytical and test data underlying the disclosure.

On behalf of the Board of Directors

Kimberly Ann

Founder, CEO, President, Executive Chair

FOR FURTHER INFORMATION, PLEASE CONTACT:

Lahontan Gold Corp.

Kimberly Ann

Founder, CEO, President, Executive Chair

Phone: 1-530-414-4400

Email:
Kimberly.ann@lahontangoldcorp.com

Website: www.lahontangoldcorp.com

Cautionary Note Regarding Forward-Looking Statements:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the TSXV. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/20a2bb0c-6da0-4051-9a55-564b48955150
https://www.globenewswire.com/NewsRoom/AttachmentNg/22f0b7db-2c91-4ce4-ae55-d325c84d506f

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo –

–Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo –

– Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events–

– Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program –

– Company to host a conference call to discuss the data today, September 15 at 8:00 a.m. ET –

SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced topline results from its global phase 2 study evaluating rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as an add-on treatment for acute exacerbations in adult and adolescent participants with asthma and type 2 inflammation.

“Topline data from our Seabreeze STAT asthma trial for rademikibart supports its potential to meaningfully improve outcomes for patients in the critical period after an exacerbation,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Today’s data highlight the statistically significant rapid improvements in FEV1 within one week post treatment as well as a 66% reduction in treatment failures at 28 days, although that endpoint did not reach statistical significance. The overall results of this study provide a clear roadmap for design of a Phase 3 program. Taken together with updated market research showing approximately 1.6M ED visits in 2025 for acute asthma exacerbation by high-T2 patients, we believe these results support the potential of rademikibart to deliver significant patient impact and reduce the health economic burden for patients and hospitals. Looking ahead, we intend to report topline data from our Phase 2 Seabreeze STAT chronic obstructive pulmonary disease (COPD) trial later this month. Following which we plan to engage with the FDA regarding a Phase 3 registrational development program for rademikibart as add-on treatment for acute exacerbations of asthma and COPD.”

“Patients who experience acute exacerbations remain at an elevated risk for subsequent exacerbations and worsening of symptoms despite current standard-of-care,” said Michael Wechsler, MD, Director of the Cohen Family Asthma Institute and Professor of Medicine at National Jewish Health in Denver, Colorado. “66% reduction in treatment failure is an exceptional outcome and is particularly impressive and shows a meaningful improvement over standard-of-care therapy alone. The ability to deliver this magnitude of benefit while also significantly improving lung function underscores the potential of rademikibart to improve outcomes and establish a new treatment paradigm for managing acute exacerbations in the hospital setting.”

The Phase 2 Seabreeze STAT Asthma study (CBP-201-206) is a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in adult and adolescent participants with asthma and type 2 inflammation. The study enrolled 160 patients who were randomized 1:1 to receive either a 600mg dose of rademikibart (n=79) or placebo (n=81), administered subcutaneously in addition to standard of care. The primary endpoint was treatment failure, defined as death due to any cause, (re)admission to a hospital for asthma, emergency department (ED) (re)visit or unscheduled medical visit for worsening of asthma symptoms, or the necessity to intensify pharmacologic treatment within 28 days after randomization. The key secondary endpoint was absolute change from baseline in post-bronchodilator (post-BD) forced expiratory volume in one second (FEV1) at Week 1, which is also the proposed primary endpoint for Phase 3.
Key topline results include:

  • Rademikibart demonstrated a statistically significant increase from baseline in post-bronchodilator FEV1 on Day 7 of 250 mL compared to 120 mL with placebo (130mL greater improvement compared to placebo; p=0.023)
  • Rademikibart reduced the treatment failure rate by approximately 66% over 28 days compared to placebo (p=0.153).
    • The endpoint missed statistical significance due to an overall lower treatment failure rate than projected
  • 50% reduction in emergency department visits or unscheduled medical visits for worsening asthma symptoms compared to placebo
  • Rademikibart was well tolerated and no new safety signals were observed through the end of the study. The safety profile was comparable to placebo, with a low incidence of adverse events (AEs) in both arms, no individual AE occurring in more than 2 participants, no AEs leading to study discontinuation in either arm, and one serious adverse event (SAE) reported in the rademikibart arm compared to 3 SAEs in the placebo arm.

Connect expects to report topline data from the ongoing Phase 2 Seabreeze STAT COPD study (CBP-201-207) of rademikibart for the treatment of acute exacerbations in COPD patients with type 2 inflammation later this month and plans to move quickly to meet with the FDA to gain alignment on a Phase 3 program.

Company-Hosted Conference Call and Webcast

Connect will host a conference call and webcast today, September 15, 2026, at 8:00 a.m. ET. To access the conference call, please pre-register through here to receive dial-in information and a personal PIN to access the live call. Participants may access the live webcast here or from the Investors section of the Connect website at investors.connectbiopharma.com. An archive of the webcast and presentation will be available for approximately 90 days after the event.

About the Seabreeze STAT Asthma Study

Seabreeze STAT Asthma is a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in adult and adolescent participants with asthma and type 2 inflammation. The study has enrolled 160 participants globally with an eosinophil count of ≥300 cells/μL who have experienced an acute asthma exacerbation. Participants received either a single dose of rademikibart or placebo, administered subcutaneously. The primary endpoint is treatment failure rate over 28 days following an acute exacerbation. The key secondary endpoint is post-bronchodilator (post-BD) forced expiratory volume in one second (FEV1) at Week 1. Other secondary endpoints include rate and time to new asthma exacerbations, change-from-baseline in asthma symptom score and nocturnal awakenings, post-BD FEV1 at other timepoints, and incidence of adverse events for 8 weeks after dosing. For more information, please visit clinicaltrials.gov (identifier NCT06940141).

About Rademikibart

Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis, asthma and COPD.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial and operating results and related expectations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), statements regarding the timing or results of any interim analysis or interim, topline or preliminary data and whether such analysis or data is indicative of safety, efficacy, final trial results or likelihood of regulatory approval for our product candidates, planned or expected meetings with the FDA or any other regulatory authorities, planned or expected product approval applications or approvals, anticipated milestones and milestone payments, expected data readouts and enrollments and the timing thereof, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations, market opportunities and potential pricing strategies for our prospective products, if approved, our plans for rademikibart, including potential indications, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; the timing and outcome of any meetings with the FDA or other regulatory authorities regarding further development of our product candidates, including with respect to a potential Phase 3 program for rademikibart; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community; the impact on our business of adverse global macroeconomic and geopolitical conditions, including high interest rates, the inflationary environment, recessionary fears, foreign exchange rate volatility, instability in financial institutions, government shutdowns, changes in monetary policy, changes in trade policies, including tariffs and other trade restrictions or the threat of such actions, and rising geopolitical instability, including the conflicts in the Middle East and the related volatility in the price of oil and other commodity prices; as well as the risks and uncertainties described in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, our subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC .

Words such as “aim,” “anticipate,” “believe,” “commitments,” “continue,” “could,” “design,” “estimate,” “expect,” “feel,” “goal,” “intend,” “may,” “might,” “objective,” “optimistic,” “plan,” “potential,” “predict,” “promising,” “seek,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results or outcomes, or the timing of such results or outcomes, may differ materially from those expressed or implied in our forward-looking statements due to the risks and uncertainties described above. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated herein. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date hereof. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the FDA, the NMPA, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Investor Relations Contact:

Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

Bogota, Colombia, Sept. 15, 2026 (GLOBE NEWSWIRE) — GeoPark Limited (NYSE: GPRK) (the “Company” or “GeoPark”) today announced that it is soliciting consent (the “Consent Solicitation”) from the holders of its 8.750% Senior Notes due 2030 (the “Notes”) for the adoption of a certain proposed amendment (the “Proposed Amendment”) to the indenture governing the Notes (the “Indenture”) to amend the definition of “Permitted Holders” in the Indenture to include Jaime Gilinski Bacal and his Immediate Family Members (as defined in the Indenture) or the former spouses (including widows and widowers), heirs or lineal descendants of any of the foregoing and any Affiliate of any of the foregoing. Jaime Gilinski Bacal is affiliated with Grupo Gilinski, which through affiliated entities has through a number of transactions recently purchased approximately 28% of the Company’s issued and outstanding common shares. GeoPark’s recently announced proposed major strategic entry into Venezuela through the Bare field, a large-scale producing heavy oil asset located in the Orinoco Heavy Oil Belt, was led by Grupo Gilinski. GeoPark is acquiring Grupo Gilinski’s 95% interest in the holding company through which the Bare opportunity is held in exchange for newly issued common shares. The proposed transaction has not yet closed and remains subject to certain conditions. Upon completion of the share issuance, Grupo Gilinski is expected to hold approximately 56.3% of GeoPark’s issued and outstanding common shares. Pursuant to the Indenture, a “Change of Control” will generally not be triggered by the consummation of a transaction the result of which is that a Permitted Holder becomes the beneficial owner of more than 50% of the outstanding shares. Pursuant to the Indenture, if a Change of Control occurs, the Company is required to make an Offer to Purchase (as defined in the Indenture) for all of the outstanding Notes.

The Consent Solicitation is being made pursuant to a Consent Solicitation Statement, dated September 15, 2026 (as may be amended or supplemented from time to time, the “Consent Solicitation Statement”). The Consent Solicitation was commenced today and will expire at 5:00 p.m., New York City time, on September 23, 2026, unless extended by the Company (each such date and time, as the same may be extended, is referred to as the “Expiration Time”). Only holders of the Notes as of 5:00 p.m., New York City time, on September 14, 2026 (such date and time, including as such date and time may be changed by the Company, from time to time, the “Record Date”) are entitled to consent to the Proposed Amendment pursuant to the Consent Solicitation.

The Proposed Amendment will be set forth in a supplemental indenture relating to the Notes and are described in more detail in the Consent Solicitation Statement. To amend the Indenture, the Company must receive consents from holders (as of the Record Date) representing a majority in aggregate principal amount outstanding (not including any Notes which are owned by the Company or any of its affiliates) of the Notes (the “Requisite Consents”).

With respect to the Consent Solicitation, the Company will, within five business days of the Expiration Time, provided that all applicable conditions to the Consent Solicitation as described in the Consent Solicitation Statement have been satisfied or waived, pay to holders of the Notes, a cash payment equal to $2.50 per $1,000 principal amount of Notes in respect of which such consents have been validly delivered prior to the Expiration Time and not validly revoked by such holders as total consideration for such consent (the “Consent Fee”). No Consent Fee will be paid to any holder of Notes unless such holder delivers a consent in accordance with the terms of the Consent Solicitation Statement prior to the Expiration Time. The consummation of the Consent Solicitation is conditioned on the receipt of the Requisite Consents.

Subject to applicable law, the Company reserves the right, in its sole discretion, to (i) extend, terminate or withdraw the Consent Solicitation at any time, or (ii) otherwise amend the Consent Solicitation in any respect, including waiving any or all of the conditions to the Consent Solicitation set forth in the Consent Solicitation Statement, at any time and from time to time. The Company further reserves the right, in its sole discretion, not to accept any deliveries of consents with respect to the Notes. The Company is making the Consent Solicitation only in those jurisdictions where it is legal to do so.

Banco BTG Pactual S.A. – Cayman Branch is acting as solicitation agent for the Consent Solicitation and can be contacted at Banco BTG Pactual S.A. – Cayman Branch, Attn: Debt Capital Markets +1 (646) 924-2500, with questions regarding the Consent Solicitation.

Copies of the Consent Solicitation Statement are available to holders of Notes from D.F. King & Co., Inc., the information agent, tabulation agent and paying agent for the Consent Solicitation. Requests for copies of the Consent Solicitation Statement should be directed to D.F. King at +1 (800) 967-5084 (toll free), +1 (212) 269-5550 (collect) or geopark@dfking.com.

Neither the Consent Solicitation nor any related documents have been filed with the U.S. Securities and Exchange Commission, nor have any such documents been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Consent Solicitation Statement or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.

The Consent Solicitation is being made solely on the terms and conditions set forth in the Consent Solicitation Statement. Under no circumstances shall this press release constitute an offer to buy or the solicitation of an offer to sell the Notes or any other securities of the Company or any of its affiliates. The Consent Solicitation is not being made to, nor will the Company accept deliveries of consents from, holders in any jurisdiction in which the Consent Solicitation or the acceptance thereof would not be in compliance with the securities or blue sky laws of such jurisdiction. This press release also is not a solicitation of consents to the Proposed Amendment to the Indenture. No recommendation is made as to whether holders should deliver their consents with respect to the Notes. Holders should carefully read the Consent Solicitation Statement because it contains important information, including the various terms and conditions of the Consent Solicitation.

ABOUT GEOPARK

GeoPark is a leading independent energy company with over 20 years of successful operations across Latin America.

For further information, please contact:  
   
INVESTORS:
 
   
Maria Catalina Escobar
Shareholder Value and Capital Markets Director
mescobar@geo-park.com
   
Miguel Bello
Investor Relations Officer
mbello@geo-park.com
   
Maria Alejandra Velez
Investor Relations Leader
mvelez@geo-park.com
   
MEDIA:
 
   
Communications Department communications@geo-park.com
   

CAUTIONARY STATEMENTS RELEVANT TO FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are preceded by words such as “believes,” “expects,” “may,” “anticipates,” “plans,” “intends,” “assumes,” “will” or similar expressions. The forward-looking statements contained herein include statements about the consent solicitation, the acquisition of our common shares by Jaime Gilinski Bacal and Grupo Gilinski, and the proposed major strategic entry into Venezuela through the Bare field. These expectations may or may not be realized. Some of these expectations may be based upon assumptions or judgments that prove to be incorrect. In addition, GeoPark’s business and operations involve numerous risks and uncertainties, many of which are beyond the control of GeoPark, which could result in GeoPark’s expectations not being realized or otherwise materially affect the financial condition, results of operations and cash flows of GeoPark. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are described in GeoPark’s filings with the United States Securities and Exchange Commission.

The forward-looking statements are made only as of the date hereof, and GeoPark does not undertake any obligation to (and expressly disclaims any obligation to) update any forward-looking statements to reflect events or circumstances after the date such statements were made, or to reflect the occurrence of unanticipated events. In light of the risks and uncertainties described above, and the potential for variation of actual results from the assumptions on which certain of such forward-looking statements are based, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this document may not occur, and that actual results may vary materially from those described herein, including those described as anticipated, expected, targeted, projected or otherwise.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.